2022-503026-12-00招募中3 期
Efficacy and safety of infliximab for immune checkpoint inhibitor induced colitis: a multinational, randomised, open label, phase III trial - The iCaD Study
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 3
- 主要终点
- Time (days) to persistent modified CTCAE (mCTCAE; definition according to Table 3) grade ≤ 1 ir-colitis/diarrhoea. Persistent is defined as grade ≤ 1 ir-colitis/diarrhoea for five consecutive days or more with no increase in corticosteroid intake, and the event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: seven weeks)
研究概览
简要总结
The objectives of the study are to compare the efficacy and safety of an anti-inflammatory regimen consisting of initial infliximab concomitant to corticosteroid to corticosteroid alone for the treatment of severe ICI induced colitis/diarrhoea.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Untreated mCTCAE grade 2-4 diarrhoea or colitis, or persistent mCTCAE grade 2 diarrhoea after administration of loperamide or equivalent for mCTCAE grade ≤ 2 diarrhoea
- •Usage of prednisolone ≤ 10 mg daily for non irAE is allowed
- •Diagnostic work up including screening for viral hepatic infection and QuantiFERON-TB for mycobacterium tuberculosis must be requisitioned but will not need to be reported prior to study enrolment
- •Women of child bearing potential must have a negative serum (preferred) or urine pregnancy test within 72 hours prior to registration. Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e. females who have had evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.
- •Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and after the study treatment: for at least 6 months after the last study treatment, or depending on the duration antineoplastic treatment Note: A highly effective method of birth control is defined as a method which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), Intrauterine device (IUD), Intrauterine hormone-releasing system (IUS), Bilateral tubal occlusion, Vasectomized partner, Sexual abstinence
- •No signs of colonic perforation or infection
- •Understands the nature and purpose of the study and the study procedures and has signed informed consent
- •Is able to read, understand, and complete questionnaires and daily components of the Patient Diary for the study period
- •Histologically confirmed malignant solid tumours
- •Treatment with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 or anti-PD-L1) within the past 12 weeks. Immune checkpoint inhibitors can be administered as single agents or as combination therapy with anti-CTLA-4 and anti-PD-1
- •No probability of a concomitant treatment (e.g. laxatives) other than the immune checkpoint inhibitor being the causal drug for the colitis or diarrhoea
- •Prior treatment with immune checkpoint inhibitors is allowed
排除标准
- •Prior history of inflammatory bowel disease, colitis, or diarrhoea requiring treatment with any corticosteroid, or any other immunosuppressant medication
- •Prior history of recurrent bowel disease including symptomatic diverticulosis
- •Current positive testing for Clostridium difficile or other colonic infection
- •Current bacterial infection requiring antibiotic treatment, or systemic fungal infection
- •Ongoing antibiotic treatment for any reason
- •Treatment with systemic corticosteroids within the last four weeks prior to study enrolment (daily usage of prednisolone ≤ 10 mg for non irAE conditions is accepted)
- •Concurrent immune-related adverse events requiring immunosuppressant medication of any kind
- •Known hypersensitivity or contraindications to systemic corticosteroids or infliximab
- •Prior history of viral hepatitis with a positive viral load, known untreated mycobacterium tuberculosis, or known active herpes zoster infection
结局指标
主要结局
Time (days) to persistent modified CTCAE (mCTCAE; definition according to Table 3) grade ≤ 1 ir-colitis/diarrhoea. Persistent is defined as grade ≤ 1 ir-colitis/diarrhoea for five consecutive days or more with no increase in corticosteroid intake, and the event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: seven weeks)
Time (days) to persistent modified CTCAE (mCTCAE; definition according to Table 3) grade ≤ 1 ir-colitis/diarrhoea. Persistent is defined as grade ≤ 1 ir-colitis/diarrhoea for five consecutive days or more with no increase in corticosteroid intake, and the event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: seven weeks)
次要结局
- Proportion of study subjects with grade ≤ 1 ir-colitis/diarrhoea at 72 hours (time frame: 72 hours)
- Proportion of study subjects with persistent grade ≤ 1 ir-colitis/diarrhoea at three weeks. Persistent is defined as grade ≤ 1 ir-colitis/diarrhoea for five consecutive days or more, and the event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: three weeks)
- Proportion of study subjects with a corticosteroid-free clinical remission (grade ≤ 1 ir-colitis/diarrhoea) after seven weeks (time frame: seven weeks)
- Proportion of study subjects requiring rescue immunosuppressive medication; Arm A (initial corticosteroid only): infliximab if no improvement to grade ≤ 2 ir-colitis/diarrhoea after 3 days (time frame: seven weeks); Arm B (initial infliximab): second dose infliximab according to physicians decision if no improvement to grade ≤ 2 ir-colitis/diarrhoea after seven days
- Cumulative corticosteroid exposure (time frame: seven weeks)
- QoL by means of EORTC-QLQ-C30 questionnaire and selected PRO-CTCAE items at baseline, 3, 12, 24, and 52 weeks after randomisation (time frame: 52 weeks)
- Proportion of study subjects with treatment related adverse events as assessed by CTCAE v5.0 (time frame: 12 weeks)
- Proportion of study subjects with colectomy or colitis-specific mortality (time frame: seven weeks)
- Proportion of study subjects with recurrence of ir-colitis/diarrhoea on subsequent reintroduction of ICI
- Subgroup analyses stratified for ipilimumab containing ICI for time (days) to persistent grade ≤ 1 ir-colitis/diarrhoea. Persistent is defined as grade ≤ 1 ir-colitis/diarrhoea for five consecutive days or more, and the event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: seven weeks)
- Progression Free Survival stratified by cancer type (time frame: duration of time from start of randomisation to time of progression or death, whichever occurs first or up to 24 months)
- Overall Survival stratified by cancer type (time frame: the duration of time from start of randomisation to time of death or up to 24 months)
- Translational research projects to explore the diversity and evolution of the immunologic cells and faecal microbiome from initiation of immune checkpoint inhibition, to the event of ir-colitis/diarrhoea, and to resolution after immunosuppressive therapy
研究者
Stefan Starup Jeppesen
Scientific
Odense University Hospital
研究点 (3)
Loading locations...
相似试验
招募中
3 期
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced ColitisColitisNCT05947669Odense University Hospital195
招募中
1 期
The iCaD StudyImmune checkpoint inhibitor related colitisCTIS2022-503026-12-00Odense University Hospital225
招募中
4 期
Combined Immunosuppression for Pediatric Crohn's DiseaseInfliximabImmunosuppressionChildren, OnlyCrohn DiseaseNCT05043870Children's Hospital of Fudan University128
终止
不适用
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory DiseasesInflammatory Bowel DiseasesNCT03370601University Hospital, Lille9
终止
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell ArteritisGiant Cell ArteritisNCT00076726Centocor, Inc.44